Difficulty: Medium
Average Score: 76%
Practice
Infliximab:
Correct answer
A
Rationale
Rationale:
Infliximab is a monoclonal antibody that acts by inhibiting tumor necrosis factor (TNF), making option A correct. TNF is a proinflammatory cytokine implicated in various inflammatory diseases, including Crohn's disease and ulcerative colitis. Therefore, infliximab is used to target and neutralize TNF, reducing inflammation in conditions like inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Option B is incorrect because infliximab can be administered multiple times as needed, not limited to a single occasion. Patients may develop antibodies against infliximab over time, reducing its effectiveness, but this does not restrict it to a single administration.
Option C is incorrect because infliximab is not licensed for the management of irritable bowel syndrome (IBS), but rather for more severe inflammatory conditions like Crohn's disease and ulcerative colitis.
Option D is incorrect because infliximab is indeed used for induction and maintenance therapy in Crohn's disease and ulcerative colitis, making it an important option for managing these chronic inflammatory conditions.
Educational Context:
Understanding the mechanism of action of drugs targeting the gastrointestinal system is crucial in the treatment of various gastrointestinal disorders. In the case of infliximab, knowing that it inhibits TNF helps in comprehending its role in managing conditions like Crohn's disease and ulcerative colitis. Recognizing the correct indications and limitations of drugs like infliximab is essential for healthcare professionals to make informed decisions in clinical practice.
Infliximab is a monoclonal antibody that acts by inhibiting tumor necrosis factor (TNF), making option A correct. TNF is a proinflammatory cytokine implicated in various inflammatory diseases, including Crohn's disease and ulcerative colitis. Therefore, infliximab is used to target and neutralize TNF, reducing inflammation in conditions like inflammatory bowel disease (Crohn's disease and ulcerative colitis).
Option B is incorrect because infliximab can be administered multiple times as needed, not limited to a single occasion. Patients may develop antibodies against infliximab over time, reducing its effectiveness, but this does not restrict it to a single administration.
Option C is incorrect because infliximab is not licensed for the management of irritable bowel syndrome (IBS), but rather for more severe inflammatory conditions like Crohn's disease and ulcerative colitis.
Option D is incorrect because infliximab is indeed used for induction and maintenance therapy in Crohn's disease and ulcerative colitis, making it an important option for managing these chronic inflammatory conditions.
Educational Context:
Understanding the mechanism of action of drugs targeting the gastrointestinal system is crucial in the treatment of various gastrointestinal disorders. In the case of infliximab, knowing that it inhibits TNF helps in comprehending its role in managing conditions like Crohn's disease and ulcerative colitis. Recognizing the correct indications and limitations of drugs like infliximab is essential for healthcare professionals to make informed decisions in clinical practice.